Targeted biologic therapies under evaluation for SLE include anifrolumab, belimumab (intravenous and subcutaneous formulations were registered by FDA for use in SLE in 2017) and off-label rituximab, abatacept, tocilizumab, obintuzumab, and eculizumab.[3] The novel biologic therapy, telitacicept, is currently under investigation
Why not take the hassle out of meal planning and prepping with Territorys GLP-1 Companion Meals
Not a quiz
Recalls & Warnings December 10, 2014 Risk of Fungal Infection from Probiotics in People with Weakened Immune System On December 9, 2014, the FDA warned that supplements containing live bacteria or yeast have the potential to be contaminated with mold, and may pose a risk of potentially deadly fungal infection in immunocompromised persons
Can laser treatment permanently remove spots on the face